WMT

95.62

+1.14%↑

COST

970.4

+0.04%↑

KR

70.73

-1.57%↓

TGT

96.28

+3.66%↑

STZ

184.25

-0.76%↓

WMT

95.62

+1.14%↑

COST

970.4

+0.04%↑

KR

70.73

-1.57%↓

TGT

96.28

+3.66%↑

STZ

184.25

-0.76%↓

WMT

95.62

+1.14%↑

COST

970.4

+0.04%↑

KR

70.73

-1.57%↓

TGT

96.28

+3.66%↑

STZ

184.25

-0.76%↓

WMT

95.62

+1.14%↑

COST

970.4

+0.04%↑

KR

70.73

-1.57%↓

TGT

96.28

+3.66%↑

STZ

184.25

-0.76%↓

WMT

95.62

+1.14%↑

COST

970.4

+0.04%↑

KR

70.73

-1.57%↓

TGT

96.28

+3.66%↑

STZ

184.25

-0.76%↓

Search

Compass Pathways Plc ADR

Suletud

3.98 0.76

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.6

Max

3.98

Põhinäitajad

By Trading Economics

Sissetulek

-4.4M

-43M

Aktsiakasum

-0.63

Töötajad

166

EBITDA

513K

-41M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+343.97% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-11M

331M

Eelmine avamishind

3.22

Eelmine sulgemishind

3.98

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Compass Pathways Plc ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. veebr 2025, 18:52 UTC

Suurimad hinnamuutused turgudel

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Võrdlus sarnastega

Hinnamuutus

Compass Pathways Plc ADR Prognoos

Hinnasiht

By TipRanks

343.97% tõus

12 kuu keskmine prognoos

Keskmine 17.67 USD  343.97%

Kõrge 45 USD

Madal 9 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Compass Pathways Plc ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.57 / 4.035Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

No Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.